Show simple item record

dc.contributor.authorYazıcı, Ozan
dc.contributor.authorŞendur, M. Ali Nahit
dc.contributor.authorÖzdemir, Nuriye
dc.contributor.authorAksoy, Sercan
dc.date.accessioned2020-02-27T06:35:42Z
dc.date.available2020-02-27T06:35:42Z
dc.date.issued2016
dc.identifier.issn1007-9327
dc.identifier.urihttps://doi.org/10.3748/wjg.v22.i2.471
dc.identifier.urihttp://hdl.handle.net/11655/22218
dc.description.abstractAdvanced gastric cancer (AGC) is associated with a high mortality rate and, despite multiple new chemotherapy options, the survival rates of patients with AGC remains poor. After the discovery of targeted therapies, research has focused on the new treatment options for AGC. In the last two decades, many targeted molecules were developed against AGC. Currently, two targeted therapy molecules have been approved for patients with AGC. In 2010, trastuzumab was the first molecule shown to improve survival in patients with HER2-positive AGC as part of a first-line combination regimen. In 2014, ramucirumab was the second targeted molecule to improve survival rates and was suggested as treatment for patients with AGC who had progressed after first-line platinum plus fluoropyrimidine with or without anthracycline chemotherapy. Ramucirumab was the first targeted therapy acting as a single agent in patients with advanced gastroesophageal cancers. Although these two molecules were introduced into clinical use, many other promising molecules have been tested in phase I - II trials. It is obvious that in the near future many different targeted therapies will be in use for treatment of AGC. In this review, the current status of targeted therapies in the treatment of AGC and gastroesophageal junction tumors, including HER (2-3) inhibitors, epidermal growth factor receptor inhibitors, tyrosine kinase inhibitors, antiangiogenic agents, c-MET inhibitors, mammalian target of rapamycin inhibitors, agents against other molecular pathways fibroblast growth factor, Claudins, insulin-like growth factor, heat shock proteins, and immunotherapy, will be discussed.tr_TR
dc.language.isoentr_TR
dc.publisherBaishideng Publishing Group Inctr_TR
dc.relation.isversionof10.3748/wjg.v22.i2.471tr_TR
dc.rightsinfo:eu-repo/semantics/openAccesstr_TR
dc.subjectTargeted therapiestr_TR
dc.subjectAntibodiestr_TR
dc.subjectGastric cancertr_TR
dc.subjectTyrosine kinasetr_TR
dc.subjectSurvivaltr_TR
dc.subject.lcshR/W - Tıptr_TR
dc.titleTargeted Therapies in Gastric Cancer and Future Perspectivestr_TR
dc.typeinfo:eu-repo/semantics/articletr_TR
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.relation.journalWorld Journal Of Gastroenterologytr_TR
dc.contributor.departmentTemel Onkolojitr_TR
dc.identifier.volume22tr_TR
dc.identifier.issue2tr_TR
dc.identifier.startpage471tr_TR
dc.identifier.endpage489tr_TR
dc.indexingWoStr_TR
dc.indexingScopustr_TR
dc.fundingYoktr_TR


Files in this item

This item appears in the following Collection(s)

Show simple item record